Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis
NCT03198572Phase 2Terminated
- Sponsor
- Fudan University
- Start
- Aug 2017
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing Berberine with Placebo (2 arms). Primary endpoint: Improvement in histologic features of nonalcoholic steatohepatitis by NAFLD activity score (NAS) at 48 weeks. Started Aug 2017; status: terminated.
02
Drugs
berberine
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03198572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198572.